Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06889883
Recruiting Observational

Development and Validation of a Blood Test for Early Diagnosis of Colorectal Cancer

NCT06889883 · tracked via the Priya Life Science Spain tracker
Sponsor
ADVANCED MARKER DISCOVERY S.L
Phase
Observational
Started
2023-06-06
Last updated
2025-10-01

Condition(s) studied

Colorectal CarcinomaAdvanced Adenomas (AA)

Study summary

This is a prospective, multicenter, case-control study. The aim is to develop an optimized algorithm by combining the levels of molecular markers in plasma together with risk factors for developing colorectal cancer and clinical data of patients diagnosed with CRC or AA and healthy individuals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Patients over the age of 18 who are able to understand the participant information and sign the informed consent. * Patients who are going to undergo colonoscopy or surgical resection for tumor (CRC). Exclusion Criteria: * Patients who had developed any type of cancer in the 5 years prior to their participation in this study. * Patients who have received previous chemotherapy or radiotherapy. * Patients diagnosed with non-advanced adenomas, serrated polyps, Familial Adenomatous Polyposis or Lynch Syndrome. * Patients with inadequate bowel preparation for colonoscopy. * Patients who have undergone colonoscopy/polipectomy in the previous 5 years. * Patients with hemolyzed plasma.

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
Hospital Clinico Universitario Lozano Blesa Zaragoza Aragon Recruiting
Hospital Universitario de Cruces Bilbao Basque Country Recruiting
Policlinica Gipuzkoa Hospital Donostia / San Sebastian Basque Country Completed
Hospital Universitario Marques de Valdecilla Santander Cantabria Terminated
Hospital Universitario de Salamanca Salamanca Castille and León Recruiting
Hospital Sant Rafael Barcelona Catalonia Completed
Hospital Universitario Vall d' Hebron Barcelona Catalonia Completed
MD Anderson Cancer Centre Madrid Madrid Active Not Recruiting
Hospital Centro Médico de Asturias Oviedo Principality of Asturias Recruiting

More ADVANCED MARKER DISCOVERY S.L. trials in Spain

Observational Cross-reactivity Study for Colorectal Cancer Diagnosis Recruiting
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection Recruiting
Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme Recruiting

Other trials for the same condition

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab Starting soon
Evaluation of PreveCol's Efficiency As a Second Line Method for the Early Colorectal Cancer Detection Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06889883 on ClinicalTrials.gov ↗ ← All trials in Spain